SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents). (2nd January 2020)

• Record Type: Journal Article
• Authors: Luan, Jing; Gao, Xingchun; Hu, Fengrui; Zhang, Yuelin; Gou, Xingchun
• Is Part Of: Journal of drug targeting. Volume 28:Number 1(2020)
• Page Start: 33
• Page End: 40
• Publication Date: 2020-01-02
• Subjects: SLFN11 -- therapeutic target -- sensitivity -- DDAs -- cancers; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2019.1616746
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: In patients with cancer, drug tolerance often occurs during the use of chemotherapy drugs, seriously affecting patient prognosis and survival. Therefore, scientists began to study the factors that affect chemotherapy drug sensitivity, and the high correlation between Schlafen-11 (SLFN11) and sensitivity to chemical drugs (mainly DNA-damaging agents, DDAs) has received increasing attention since it was discovered through bioinformatics analyses. Regarding the mechanism, SLFN11 may sensitise cells to chemotherapy drugs by preventing DNA damage repair. In recent years, SLFN11 has gradually become a hot research topic, and the results are enriching our understanding of this molecule. Indeed, the biological functions of SLFN11 under normal physiological conditions and in cancer, changes in its expression levels and mechanisms promoting apoptosis within the context of chemotherapeutic interventions have gradually been uncovered. Studies to date provide knowledge and the experimental and theoretical bases underlying SLFN11 and its effects on sensitivity to chemotherapy drugs. This review summarises the existing research on SLFN11 with the aim of achieving a more comprehensive understanding and furthering the development of strategies to target SLFN11 in the treatment of cancer.